证券代码：002570 证券简称：贝因美 公告编号：2024-032 贝因美股份有限公司 关于控股股东及实际控制人涉诉的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 截至本公告披露日，公司控股股东贝因美集团有限公司（以下简称"贝因美 集团"）质押/冻结上市公司股份数量为 179,105,171 股，占其所持公司股份总数 的 99.16%。 本案件执行措施涉及贝因美集团前期已质押予中航信托股份有限公司的 4,800 万本公司无限售流通股和贝因美集团前期已质押予中国建设银行股份有限 公司杭州高新支行的 500 万股无限售流通股。已被司法冻结的股份后续可能因司 法裁决而引起贝因美集团被动减持，非其主观意愿行为。公司将严格遵守相关规 定，及时履行信息披露义务。敬请广大投资者谨慎决策，注意投资风险。 贝因美股份有限公司（以下简称"公司"、"本公司"）今日收到公司控股股 东贝因美集团函告，贝因美集团、实际控制人谢宏及其关联方今日收到长城国融 投资管理有限公司（以下简称"长城国融"）出具的《债权转让通知书》。前期债 权债务涉诉事项具体内容详见公司 ...

证券代码：002570 证券简称：贝因美 公告编号：2024-031 贝因美股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开的第八 届董事会第二十九次会议审议通过了《关于回购公司股份方案的议案》，公司拟 以集中竞价交易方式回购公司 A 股股票，用于公司未来实施的股权激励计划或 员工持股计划。本次回购金额不超过人民币 30,000 万元（含），不低于人民币 15,000 万元（含），回购价格不超过 5.20 元/股（含）。根据最高回购规模、回 购价格上限测算，预计回购股份数量为 5,769.23 万股，约占公司目前总股本的 5.34%。具体内容详见公司于 2024 年 1 月 16 日披露于指定信息披露媒体及巨潮 资讯网（http://www.cninfo.com.cn）上的《关于以集中竞价交易方式回购公司股 份方案的公告》（公告编号：2024-007）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的 ...

证券代码：002570 证券简称：贝因美 公告编号：2024-030 贝因美股份有限公司 关于回购公司股份的进展公告 一、回购股份的进展情况 截至 2024 年 2 月 29 日，公司通过股份回购专用证券账户以集中竞价交易方 式累计回购公司股份 14,745,500 股，占公司总股本的 1.37%，最高成交价为 3.90 元/股，最低成交价为 2.90 元/股，成交总金额为 49,990,187.00 元（不含交易费 用）。 公司股份回购的实施符合公司回购方案及相关法律法规的要求。 二、其它说明 时段符合《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定。 1、公司未在下列期间回购公司股票： （1）自可能对公司证券及其衍生品种交易价格产生重大影响的重大事项发 生之日或者在决策过程中，至依法披露之日内； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开的第八 届董事会第二十九次会议审议通过了《关于回购公司股份方案的议案》，公司拟 以集中竞价交易 ...

证券代码：002570 证券简称：贝因美 公告编号：2024-029 贝因美股份有限公司 关于控股股东部分股份解除质押及质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 截至本公告披露日，公司控股股东贝因美集团有限公司质押/冻结上市公司 股份数量为 179,105,171 股，占其所持公司股份总数的 99.16%。请投资者注意相 关风险。 贝因美股份有限公司（以下简称"公司"、"本公司"）近日接到公司控股 股东贝因美集团有限公司（以下简称"贝因美集团"）关于将本公司部分股份解 除质押及质押的《告知函》，具体事项如下： 一、 股东本次解除质押及质押的基本情况 1、股份解除质押的基本情况 | 股东名称 | 是否为控股 | 本次解除质 | 质押开始 | 解除质押 | | 本次解除质 | 本次解除质 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 股东及一致 | 押股数 | 日期 | 日期 | 质权人 | 押占其所持 | 押占公司总 | | | 行动人 | （股） | | | | ...

证券代码：002570 证券简称：贝因美 公告编号：2024-028 贝因美股份有限公司 关于控股股东质押证券处置的进展公告 公司控股股东贝因美集团有限公司保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 截至本公告披露日，公司控股股东贝因美集团有限公司及其一致行动人合计 持有 180,629,471 股上市公司股份，占上市公司总股本的 16.72%，其中，质押/ 冻结上市公司股份数量为 179,105,171 股，占其所持公司股份总数的 99.16%。请 投资者注意相关风险。 | 股东名称 | 股份性质 | 本次处置过户完成前 | | 本次处置过户完成后 | | | --- | --- | --- | --- | --- | --- | | | | 持股数量 | 占总股本 | 持股数量 | 占总股本 | | | | （股） | 比例 | （股） | 比例 | | 贝因美集团 | 合计持有股份 | 191,418,500 | 17.7232% | 180,629, ...

证券代码：002570 证券简称：贝因美 公告编号：2024-027 一、回购股份的进展情况 截至 2024 年 2 月 5 日，公司通过股份回购专用证券账户以集中竞价交易方 式累计回购公司股份 11,380,000 股，占公司总股本的 1.05%，最高成交价为 3.90 元/股，最低成交价为 2.99 元/股，成交总金额为 39,983,697.00 元（不含交易费 用）。 公司股份回购的实施符合公司回购方案及相关法律法规的要求。 二、其它说明 公司回购股份的时间、回购股份数量、回购股份价格及集中竞价交易的委托 时段符合《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定。 贝因美股份有限公司 关于回购公司股份达到1%的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开的第八 届董事会第二十九次会议审议通过了《关于回购公司股份方案的议案》，同意公 司使用自有资金或自筹资金以集中竞价交易方式回购公司已发行的人民币普通 股（A 股）股票。 ...

证券代码：002570 证券简称：贝因美 公告编号：2024-026 贝因美股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2024 年 1 月 15 日召开的第八 届董事会第二十九次会议审议通过了《关于回购公司股份方案的议案》，公司拟 以集中竞价交易方式回购公司 A 股股票，用于公司未来实施的股权激励计划或 员工持股计划。本次回购金额不超过人民币 30,000 万元（含），不低于人民币 15,000 万元（含），回购价格不超过 5.20 元/股（含）。根据最高回购规模、回 购价格上限测算，预计回购股份数量为 5,769.23 万股，约占公司目前总股本的 5.34%。具体内容详见公司于 2024 年 1 月 16 日披露于指定信息披露媒体及巨潮 资讯网（http://www.cninfo.com.cn）上的《关于以集中竞价交易方式回购公司股 份方案的公告》（公告编号：2024-007）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的 ...

Financial Performance - The company's revenue for the first half of 2023 was approximately ¥1.34 billion, representing a 1.84% increase compared to the same period in 2022[24]. - Net profit attributable to shareholders was approximately ¥44.22 million, reflecting a 3.04% increase year-over-year[24]. - The company achieved operating revenue of CNY 1,341.62 million in the first half of 2023, an increase of 1.84% year-on-year[54]. - The total revenue for the company reached approximately CNY 257.39 million, with a net profit of CNY 11.83 million[83]. - The company reported a net profit of CNY 39,399,021.62 for the first half of 2023, compared to CNY 22,735,304.56 in the first half of 2022, indicating an increase of about 73.5%[173]. - The total comprehensive income for the first half of 2023 was CNY 39,399,021.62, compared to CNY 22,735,304.56 in the first half of 2022, marking an increase of approximately 73.5%[173]. - The company reported a total comprehensive income of CNY 44.2 million for the current period, reflecting a significant increase compared to the previous period[181]. Cash Flow and Investments - The net cash flow from operating activities decreased by 4.93% to approximately ¥176.94 million compared to the previous year[24]. - The net cash flow from investing activities improved by 78.30%, with a net outflow of ¥13,021,304.78 compared to ¥59,997,551.87 in the previous year[56]. - The net cash flow from financing activities increased by 44.49%, with a net outflow of ¥67,100,234.39 compared to ¥120,874,759.41 in the previous year[56]. - The company’s cash and cash equivalents increased significantly by 1,808.98% to ¥99,946,458.76 from ¥5,235,597.75, driven by improved cash flows from investment and financing activities[56]. - The cash inflow from financing activities totaled 112,393,695.68 CNY, while cash outflow was 98,869,488.27 CNY, resulting in a net inflow[178]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥3.93 billion, an increase of 1.34% from the end of the previous year[24]. - The company's total liabilities as of the end of the reporting period were CNY 2,550,703,581.39, slightly up from CNY 2,521,932,805.74 at the end of the previous year[168]. - Cash and cash equivalents at the end of the reporting period amounted to ¥780,186,326.51, representing 19.86% of total assets, a decrease of 0.73% compared to the previous year[64]. - Total current assets increased to CNY 2,143,518,721.43 as of June 30, 2023, up from CNY 2,045,284,627.03 on January 1, 2023, representing a growth of approximately 4.8%[159]. - The total liabilities of the company were 253 million yuan, which is a 9.29% increase compared to the previous year[186]. Operational Efficiency and Cost Management - The company plans to strengthen cost management and expand into new markets to enhance competitiveness amid industry risks[5]. - The operating cost for the same period was CNY 739.05 million, up 5.04% year-on-year, resulting in a comprehensive gross margin of 44.91%, a decrease of 1.68 percentage points compared to the previous year[54]. - The company plans to enhance operational efficiency by optimizing its industrial layout and reducing operational costs[87]. - The company is focusing on innovative collaborations with channel partners to enhance strategic and capital cooperation[36]. Product Development and Market Expansion - The company is focusing on expanding its product matrix to include adult nutrition products and special medical purpose formula foods[85]. - The company plans to focus on brand building and collaboration to enhance brand awareness and create popular products through various media channels[88]. - The company is exploring strategic partnerships and potential acquisitions to enhance its market presence[181]. - The company has launched the "Ainoda" series of probiotics and lactoferrin nutritional milk powder for adult customers, enhancing its product offerings[36]. Research and Development - Research and development expenses decreased by 34.85% to ¥6,969,869.31 from ¥10,698,461.48, primarily due to the completion of new national standard registrations[56]. - The company aims to enhance its technological capabilities through ongoing research and development initiatives[185]. - The company holds 24 invention patents and has registered 12 infant formula products under the new national standards[48]. Corporate Governance and Compliance - The company has no significant litigation or arbitration matters during the reporting period[113]. - The company has not faced any environmental penalties during the reporting period and adheres to strict environmental management practices[99]. - The company has established a procurement agreement with suppliers and is committed to strengthening internal control systems to ensure compliance and risk management[110]. - The financial report for the first half of 2023 has not been audited[157]. Shareholder Information - No cash dividends or stock bonuses will be distributed to shareholders for this period[9]. - The company did not distribute cash dividends or issue bonus shares for the first half of 2023[94]. - The largest shareholder, Beiyinmei Group, holds 18.19% of the shares, totaling 196,418,500 shares, with 141,850,000 shares pledged and 53,000,000 shares frozen[146]. - The company has repurchased a total of 20,245,991 shares, representing 1.87% of the total share capital, with a total transaction amount of approximately 103.76 million yuan[140].

Financial Performance - The company's operating revenue for 2021 was ¥2,345,458,993.11, a decrease of 11.99% compared to ¥2,665,134,436.24 in 2020[21] - The net profit attributable to shareholders in 2021 was ¥73,314,574.33, a significant increase of 122.61% from a loss of ¥324,279,930.45 in 2020[21] - The net cash flow from operating activities reached ¥246,743,802.53, representing a remarkable increase of 713.34% compared to ¥30,336,940.67 in 2020[21] - Basic earnings per share for 2021 were ¥0.07, a turnaround from a loss of ¥0.32 per share in 2020, marking a 121.88% improvement[21] - The total assets at the end of 2021 were ¥4,069,421,166.85, reflecting a slight increase of 0.87% from ¥4,034,293,142.99 at the end of 2020[21] - The weighted average return on equity improved to 4.78% in 2021, up by 25.70% from -20.92% in 2020[21] - The net profit after deducting non-recurring gains and losses was ¥7,296,140.06, compared to a loss of ¥481,509,592.22 in 2020, indicating a 101.52% increase[21] - The total operating revenue for the fourth quarter reached ¥687,390,826.59, with a total annual revenue of ¥2,345,458,993.11, showing a consistent performance across the quarters[26] - The net profit attributable to shareholders for the fourth quarter was ¥34,564,672.37, while the annual net profit was ¥73,309,574.33, indicating a recovery trend[26] - The net cash flow from operating activities in the fourth quarter was ¥154,918,757.64, significantly higher than the previous quarters, reflecting improved operational efficiency[26] Business Strategy and Market Position - The company is positioned among the top 20 enterprises in China's dairy industry, emphasizing its commitment to high-quality product offerings and consumer satisfaction[34] - The company has completed a full industry chain layout, integrating research, production, and sales, which enhances its competitive edge in the market[34] - The company is transitioning towards a new retail business model, achieving preliminary results in this strategic shift[34] - The government policies promoting dairy industry revitalization and consumer health awareness are expected to benefit the company's growth in the long term[33] - The company maintains a strong brand image and customer loyalty, which are crucial for sustaining its market position in the infant formula sector[34] - The company launched several new products in 2021, including "Ke Ruixin" infant formula and "Jingcai" series nutritional products, expanding its product matrix significantly[40] - The company’s ODM and OEM business has been actively expanded to optimize industrial structure and improve capacity utilization[41] - The company aims to strengthen its main product categories and expand into niche markets by optimizing product structure and enhancing user lifecycle management[97] - The company is focusing on building a reputation through user-generated content and KOL partnerships to enhance brand credibility[97] - The company is positioned to capitalize on the growing demand for healthy food products, particularly in the context of increasing consumer awareness about nutrition[124] Financial Management and Governance - The company reported a significant increase in financial expenses by 69.84% to ¥74,994,949.41, mainly due to increased exchange losses[68] - The company’s R&D expenses increased by 113.12% year-on-year, amounting to ¥26,135,300.31, primarily due to increased investment in formula registration research[68] - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management, aligning with legal regulations[111] - The company operates independently from its controlling shareholder in terms of business, personnel, assets, organization, and finance, ensuring complete operational autonomy[114] - The company’s governance structure aligns with the regulations set forth by the China Securities Regulatory Commission, with no significant discrepancies identified[113] - The company has committed to maintaining high standards in corporate governance with a well-structured board and management team[125] - The company is focusing on improving its financial management practices following regulatory feedback to enhance transparency and accuracy in reporting[130] Employee and Management Changes - The company reported a resignation of the former General Manager, Bao Xiufei, due to personal reasons on January 14, 2021[120] - The company experienced a change in its board with Director Xu Liangjun resigning on January 21, 2021, due to work-related reasons[120] - The company noted the resignation of Vice General Manager Wang Yunfang on February 9, 2021, also due to personal reasons[120] - The company’s independent director Ma Juan and director Li Jun left the board on May 21, 2021, as their term expired[120] - The company’s Vice General Manager and Chief Financial Officer Chen Bin resigned on December 22, 2021, for personal reasons[120] - The company reported a significant leadership change with the appointment of Xie Hong as both Chairman and General Manager on May 21, 2021, following the resignation of several key executives[121] - The company has seen changes in its financial management team, with the appointment of Jin Zhiqiang as the new Financial Director on December 22, 2021, reflecting a commitment to financial oversight[123] Social Responsibility and Environmental Initiatives - The company has established a comprehensive environmental management system, ensuring pollutant emissions are within regulatory limits and has not faced any environmental penalties during the reporting period[168] - The company donated 2,000 boxes of formula milk worth over 1.87 million yuan to improve local children's nutrition in Guizhou Province[169] - The company actively participated in social responsibility initiatives, including support for families with multiple births and special needs children[169] - The company emphasizes the harmonious unity of five values: customer value, employee value, shareholder value, partner value, and social value[170] - The company has implemented measures to manage carbon emissions and promote clean production practices[168] - The company has committed to continuous improvement of its corporate governance and operational standards in response to regulatory requirements[166] Related Party Transactions and Legal Matters - The company is involved in two major lawsuits with total amounts of 1,174.38 million yuan, with ongoing court proceedings[186] - The company’s controlling shareholder, Beiyinmei Group, had 4,466,576 shares frozen by the court, representing 2.10% of its total shareholding due to a dispute[188] - The company reported a related party transaction amounting to 8,125.3 million yuan for raw material procurement, which accounted for 6.22% of the total transaction amount[189] - The company has engaged in various related party transactions, including a procurement agreement with its parent company for 1,962.3 million yuan[190] - The company is actively taking measures to resolve the financial disputes with Zhejiang Construction Group[188]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,317,396,660.52, representing a 17.47% increase compared to CNY 1,121,481,666.83 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was CNY 42,914,990.66, up 28.01% from CNY 33,524,658.31 in the previous year[24]. - The net profit after deducting non-recurring gains and losses was CNY 27,356,468.67, reflecting a significant increase of 60.08% from CNY 17,088,924.55[24]. - The net cash flow from operating activities surged to CNY 186,103,264.43, a remarkable increase of 412.18% compared to CNY 36,335,620.30 in the previous year[24]. - The basic earnings per share rose to CNY 0.04, marking a 33.33% increase from CNY 0.03[24]. - The total comprehensive income for the first half of 2022 was CNY 43,719,463.40, compared to CNY 40,962,410.80 in the same period of 2021, showing an increase of 4.3%[170]. - The total profit for the first half of 2022 was CNY 48,870,125.87, a decrease from CNY 50,277,651.93 in the same period of 2021, reflecting a decline of 2.8%[170]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,079,980,580.69, a slight increase of 0.26% from CNY 4,069,421,166.85 at the end of the previous year[24]. - The company's total liabilities amounted to CNY 2,669,442,398.12 as of June 30, 2022, compared to CNY 2,519,631,052.61 at the start of the year, indicating an increase of 5.9%[166]. - The total equity attributable to shareholders reached CNY 2,116,247,124.94, up from CNY 2,092,842,220.38 at the beginning of the year, reflecting a growth of 1.1%[166]. - The company's cash and cash equivalents increased to CNY 793,428,330.71 from CNY 676,870,643.54, representing a growth of approximately 17.3%[160]. - The company's total liabilities decreased to CNY 1,785,836,479.80, indicating improved financial stability[181]. Revenue Segments - The sales revenue of children's powder increased by 286% year-on-year, while the sales of special medical formula milk powder grew by over 62.40%[37]. - Revenue from the milk powder segment was ¥1,190,471,160.39, accounting for 90.37% of total revenue, with a year-on-year growth of 18.20%[59]. - The gross profit margin for the main business was 48.55%, with a year-on-year increase of 16.44%[41]. - The gross profit margin for the infant industry was 46.59%, a decrease of 7.01% compared to the previous year[60]. Investments and R&D - The company has established six infant formula production plants and has implemented advanced management systems including MES, WMS, and ERP to enhance production efficiency[49]. - The company holds 21 invention patents and has registered 60 infant formula products, showcasing its strong R&D capabilities in the industry[48]. - Research and development expenses decreased by 28.95% to CNY 10,698,461.48, reflecting a strategic focus on cost management[55]. - The company’s R&D expenses decreased to CNY 1,320,345.28 in the first half of 2022 from CNY 348,945.37 in the previous year, indicating a significant increase in investment in innovation[172]. Market and Sales - The number of distributors increased from 1,526 at the end of 2021 to 1,685 by June 2022, marking a growth rate of 10%[42]. - The company’s e-commerce sales accounted for 16.83% of total revenue, with a year-on-year growth of 12.48%[41]. - The company launched new products including "Aijia Organic A2" and "Aijia Baohu Cover" series infant formula during the reporting period[39]. Corporate Governance and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[5]. - The company has implemented measures to enhance regulatory compliance and prevent related party investment issues[134]. - The company has not reported any issues or other situations regarding the use and disclosure of raised funds[79]. Future Outlook - The company plans to continue expanding its product offerings and market presence, focusing on innovation and strategic partnerships[63]. - Future guidance and performance outlook remain optimistic, with a focus on enhancing shareholder value[145]. - The company plans to continue focusing on improving its financial health and exploring new market opportunities in the upcoming quarters[200].